STUDY OF MALONALDEHYDE CONTENTIN THE ORAL FLUID OF PATIENTS WITH CHRONIC GENERALIZED PERIODONTITIS COMPLICATED BY OSTEOPENIA AND OSTEOPOROSIS UNDER A THERAPEUTIC AND PROPHYLACTIC COMPLEX

Abstract

Chronic generalized periodontitis (CGP) on the background of osteopenia and osteoporosis is accompanied by enhanced oxidative stress, manifested by elevated malondialdehyde (MDH) levels in oral fluid. Effective control of lipid peroxidation is therefore a requisite element of comprehensive treatment in such patients. The purpose of the study was to evaluate the efficacy of a therapeuticpreventive complex (TPC) on the dynamics of MDH content in the oral fluid of patients with CGP complicated by osteopenia and osteoporosis. Materials and methods. Twenty-five patients aged 25–55 years were examined and allocated to three groups: I – healthy controls (n=10); II – comparison group (CGP+osteopenia/osteoporosis, basic therapy only; n=12); III – main group (CGP+osteopenia/osteoporosis, basic therapy+TPC; n=13). MDH levels were determined in oral fluid; statistical significance was assessed using Student’s t-test (p < 0.01). Research results. At baseline, MDH exceeded the normative value 2.05-fold in group II (0.35 ± 0.02 mmol/L) and 1.82-fold in group III (0.31±0.02 mmol/L). After 3 months MDH decreased by 20% in group II and by 22.5% in group III. At 8 months, 1.5 years and 2 years the MDH level in group II returned to baseline, whereas group III maintained significant reductions of 51.6%, 45.2% and 35.4%, respectively; the level was two-fold lower than in group II at all corresponding time points. Conclusions. Incorporation of the TPC into basic therapy produces a statistically significant and durable attenuation of lipid peroxidation, as reflected by sustained decreases in oralfluid MDH during long-term follow-up.